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HIF-2a promotes von Hippel-Lindau (VHL)-deficient renal clear cell carcinoma (RCC) tumorigenesis,
while HIF-1a inhibits RCC growth. As HIF-1a antagonizes c-Myc function, we hypothesized that
HIF-2amight enhance c-Myc activity.We demonstrate here that HIF-2a promotes cell-cycle progres-
sion in hypoxic RCCs and multiple other cell lines. This correlates with enhanced c-Myc promoter
binding, transcriptional effects on both activated and repressed target genes, and interactions
with Sp1, Miz1, and Max. Finally, HIF-2a augments c-Myc transformation of primary mouse embryo
fibroblasts (MEFs). Enhanced c-Myc activity likely contributes to HIF-2a-mediated neoplastic pro-
gression following loss of the VHL tumor suppressor and influences the behavior of hypoxic tumor
cells.INTRODUCTION
Low oxygen (O2) levels are frequently encountered in solid
tumors, and hypoxic stress responses have important ef-
fects on the natural history of disease (Pugh and Ratcliffe,
2003). Tumor growth, angiogenesis, invasion, and metas-
tasis are all regulated by hypoxia-stimulated gene expres-
sion, largely mediated by hypoxia-inducible factors (HIFs).
HIFs function as heterodimers inwhich theO2-labile a sub-
units form a complex with a stable b subunit (also known
as ARNT) and bind hypoxia response elements (HREs)
throughout the genome. Two a subunits, HIF-1a and
HIF-2a, have been demonstrated to increase target gene
transcription in hypoxic cells. When complexed with
ARNT, they activate genes such as those encoding glyco-
lytic enzymes, vascular endothelial growth factor (VEGF),
matrix metalloproteinase-2, and erythropoietin (Hu et al.,
2003; Semenza, 2003). The HIFs can alter cell-cycle pro-gression through putative transcriptional targets such as
Cyclin D1 (Baba et al., 2003) and indirect modulation of
p21 and p27 (Gardner et al., 2001; Green et al., 2001;
Koshiji et al., 2004).
While initial characterization of hypoxia-induced tran-
scription focused on HIF-1a, HIF-2a has recently been
shown to regulate unique genes and physiologic functions
(Covello et al., 2006; Hu et al., 2003; Tian et al., 1998). The
HIF-a subunits differ in expression profiles, with HIF-1a
expressed ubiquitously and HIF-2a limited to endo-
thelium, kidney, heart, lungs, and small intestine (Ema
et al., 1997; Tian et al., 1997; Wiesener et al., 2003).
HIF-1a uniquely activates glycolytic enzyme genes, while
HIF-2a preferentially activates VEGF, transforming growth
factor-a (TGFa), lysyl oxidase, Oct4, and Cyclin D1 (Baba
et al., 2003; Covello et al., 2006; Erler et al., 2006; Gunar-
atnam et al., 2003; Hu et al., 2003; Wang et al., 2005). Tar-
geted disruption of the Hif-2a locus in different mouseSIGNIFICANCE
Activation of the hypoxia-inducible factors (HIFs) is a key feature of solid-tumor biology. Here we describe a fun-
damental distinction between the two HIF-a subunits: tumor cells expressing HIF-2a exhibit increased prolifera-
tion by promoting c-Myc transcriptional activity, while HIF-1a inhibits cell-cycle progression by opposing c-Myc.
HIF-2a’s unique enhancement of cell-cycle progression, combined with the effects of either HIF-a on angiogene-
sis, invasion, and metastasis, is likely to produce worse clinical outcomes than activation of HIF-1a alone. This is
consistent with clinical data from RCC, neuroblastoma, and colorectal and non-small-cell lung cancer and high-
lights the importance of HIF-2a as a specific target of anticancer therapy.Cancer Cell 11, 335–347, April 2007 ª2007 Elsevier Inc. 335
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HIF-2a Enhances c-Myc Activitystrains results in distinct phenotypes, including embryonic
lethality due to bradycardia and vascular defects, perina-
tal lethality due to impaired lung maturation, and embry-
onic and postnatal lethality caused by multiorgan failure
and mitochondrial dysfunction (Compernolle et al., 2002;
Peng et al., 2000; Scortegagna et al., 2003; Tian et al.,
1998). Each of these is quite different from the E10.5 le-
thality caused by cardiac and vascular defects resulting
from Hif-1a disruption (Carmeliet et al., 1998; Iyer et al.,
1998; Ryan et al., 1998).
HIF-2a, but not HIF-1a, promotes tumor growth in RCC
xenograft models. Overexpression of stable HIF-2a in
786-O RCC cells expressing pVHL restores xenograft
growth to the level of parental VHL null cells (Kondo
et al., 2002, 2003; Raval et al., 2005), whereas overexpres-
sion of stable HIF-1a inhibits tumor growth (Maranchie
et al., 2002; Raval et al., 2005). Studies of preneoplastic le-
sions from the kidneys of patients with VHL disease also
suggest a role for HIF-2a in the transformation of dysplas-
tic cells, as HIF-2a expression increased with the degree
of dysplasia, whereas HIF-1a expression decreased
(Mandriota et al., 2002; Raval et al., 2005). HIF-2a also
appears to have a more general role in promoting tumori-
genesis. Subcutaneous teratomas generated from ES
cells with the HIF-2a cDNA ‘‘knocked in’’ to the Hif-1a lo-
cus exhibit 4-fold greater mass than WT controls, largely
due to increased proliferation (Covello et al., 2005). This
is not simply the result of HIF-1a loss, as multiple studies
withHif-1a/ ES-cell-derived teratomas failed to demon-
strate a consistent growth advantage (Carmeliet et al.,
1998; Hopfl et al., 2002; Ryan et al., 1998). A recent study
in neuroblastoma has shown HIF-2a stabilization under
prolonged, but mild, hypoxia, raising the intriguing possi-
bility that HIF-2a may promote angiogenesis even in
tumors experiencing minimal hypoxic stress (Holmquist-
Mengelbier et al., 2006).
Moderate levels of hypoxia (0.5%–3% O2) can cause
cell-cycle arrest through a HIF-1a-dependent increase in
cyclin-dependent kinase inhibitor (CKI) p21 and p27 ex-
pression (Gardner et al., 2001; Goda et al., 2003; Green
et al., 2001). p21 and p27 are not direct HIF targets; their
expression changes as a result of HIF-1a inhibition of
the proto-oncogene c-Myc and consequent relief of tran-
scriptional repression at their promoters (Koshiji et al.,
2004, 2005; Mack et al., 2005). HIF-1a may antagonize
c-Myc activity by altering interaction with Sp1, one of
its cofactors (Koshiji et al., 2004, 2005). There are no
published data as yet on HIF-2a effects on cell-cycle
progression.
c-Myc is a basic-helix-loop-helix/leucine zipper (bHLH/
LZ) transcription factor that controls the G1-S cell-cycle
transition and is overexpressed in many human tumors
(Adhikary and Eilers, 2005; Nilsson and Cleveland,
2003). c-Myc activates the transcription of growth-pro-
moting genes such as Cyclin D2, ornithine decarboxylase,
and E2F1 by binding to a conserved E box (CACGTG) with
its binding partnerMax, and inhibits the expression ofmul-
tiple genes, notably p21 and p27, by binding to the tran-
scription initiator element (Inr) in a complex with Max336 Cancer Cell 11, 335–347, April 2007 ª2007 Elsevier Inc.and either Sp1 or Miz1 (Coller et al., 2000; Fernandez
et al., 2003). As c-Myc is normally labile and expressed
at low levels, it competes for Max binding with antagonis-
tic transcription factors such asMad, Mnt, andMga. Inter-
estingly, Mad/Max complexes repress expression via E
boxes, while Miz1 functions as a transcriptional activator
when bound to an Inr without c-Myc (Adhikary and Eilers,
2005).
Given that HIF-1a andHIF-2amay have opposite effects
on renal tumor growth and the established inhibitory effect
of HIF-1a on c-Myc (Koshiji et al., 2004, 2005), we hypoth-
esized that HIF-2a actually promotes c-Myc transcrip-
tional activity. This would result in enhanced cell-cycle
progression and increased tumor growth. We have exam-
ined 786-O and RCC4 RCCs with restored pVHL expres-
sion, embryonic epithelial cells (ECs), and NIH3T3 cells
and observed HIF-2a mediated enhancement of c-Myc
activity and cell-cycle progression. As a control, HIF-1a ef-
fects were also assessed in each context, and HIF-1a
exhibited the anticipated inhibition of proliferation. HIF-2a
also has a role in tumor initiation, promoting c-Myc/
RasV12G induced transformation in primary MEFs.
RESULTS
HIF-2a Enhances Cell-Cycle Progression
While HIF-1a Inhibits It
To study differential effects of HIF-a subunits on tumor
cell-cycle progression, we selected cell lines expressing
predominantly HIF-1a (HCT116 colon carcinoma cells) or
HIF-2a (WT8, 786-O RCC cells expressing pVHL). We
confirmed published data concerning HIF-a subunit ex-
pression and localization in these cells (Koshiji et al.,
2004; Maxwell et al., 1999). As expected, HCT116 cells
expressed HIF-1a in the nuclear fraction, whereas WT8
cells did not, even upon long exposures of radiographic
films. HIF-2a expression in hypoxic WT8 cells was de-
tected predominantly in the nuclear fraction. HIF-2a was
also detected in HCT116 cells, but at approximately
10% the levels observed in WT8 cells (Figure 1A). To cor-
relate these data with transcriptional targets, mRNA was
extracted from cells grown at 21% or 0.5% O2 for 24,
48, and 72 hr and analyzed by quantitative real-time
PCR (QRT-PCR). As expected, both cell lines increased
expression of the HIF-1a/HIF-2a shared target VEGF
(see Figure S1A in the Supplemental Data available with
this article online), whereas only HCT116 cells showed
elevated levels of the HIF-1a-specific target phospho-
glycerate kinase (PGK; Figure S1B; Hu et al., 2003), and
only WT8 cells increased levels of the HIF-2a-specific
target Oct4 (Figure S1C; Covello et al., 2006). Of note,
while HCT116 cells exhibited basal Oct4 expression, hyp-
oxic induction of HIF-2a in these cells had no further effect
on transcript levels, likely due to low HIF-2a protein levels.
We therefore concluded that HIF-1a is the functional
HIF-a subunit in HCT116 cells, andHIF-2a is the functional
HIF-a subunit in WT8 cells.
Given that these two cell lines exhibited differential
HIF-a expression and activity, we assessed their cell-cycle
Cancer Cell
HIF-2a Enhances c-Myc ActivityFigure 1. Differential Expression of HIF-
1a and HIF-2a in HCT116 and WT8 Cells
Correlates with Differential Cell-Cycle
Progression under Hypoxia
(A)Western blot of HIF-a expression in HCT116
(‘‘HCT’’) and WT8 cells following 4 hr incuba-
tion at 0.5% O2 shows differential expression
of HIF-a subunits. Asterisk denotes a back-
ground band. Akt and Creb immunoblots
assess loading and the efficiency of cellular
fractionation; Akt is present in both the nucleus
and cytoplasm, while Creb is exclusively nu-
clear.
(B) Representative BrdU incorporation plots
from HCT116 and WT8 cells grown at 21% or
0.5% O2 for 48 hr.
(C) Summary of changes in BrdU incorporation
in HCT116 andWT8 cells after 24, 48, and 72 hr
hypoxia. Results averaged from three experi-
ments; error bars indicate ±1 SEM, *p < 0.05,
**p < 0.01.
(D) Proliferation measured by serial cell counts
under normoxia (N) or hypoxia (H); data from
one representative experiment. Error bars
indicate ±1 SD.progression by BrdU incorporation. When the HCT116
cells were grown under hypoxia, they accumulated in G1
phase with a corresponding decrease in the percentage
of cells in S phase. Representative FACS plots (Figure 1B,
upper panel) and the summary of three experiments (Fig-
ure 1C, upper panel) are shown. These changes were
statistically significant following 48 or 72 hr hypoxia (p <
0.05). Conversely, when the WT8 cells were grown at
0.5% O2, statistically significant increases in the percent-
age of cells in S phase and decreases in the percentage in
G1 phase after 24, 48 (p < 0.01), or 72 hr (p < 0.05) were
observed. Again, both representative FACS plots (Fig-
ure 1B, lower panel) and summary data (Figure 1C, lower
panel) are shown. Changes in cell-cycle profiles corre-
lated with proliferation as measured by serial cell counts
under normoxic or hypoxic conditions (Figure 1D), with
increased WT8 cell numbers and decreased HCT116
cell numbers under hypoxia. These effects are most ap-
parent at early time points, becoming attenuated after 6
days in culture due to confluency. Thus, when HIF-1a
and HIF-2a are expressed separately they have opposite
effects on cell-cycle progression and proliferation that
are stable over long time courses where HIF-2a promotes
both processes.
Given that these experiments were performed in tumor
cell lines of different tissue origins, it is possible that the
observed effects were a result of HIF-independent
hypoxic responses, or tissue-specific differences in re-
sponses to O2 deprivation. We therefore used WT8 cells
engineered to stably overexpress increasing amounts of
HIF-1a (called ‘‘1.1,’’ ‘‘1.2,’’ and ‘‘1.3’’) or HIF-2a, called
‘‘2.1’’ (Figure 2A). Cell-cycle progression was evaluatedin these cells after growth at 0.5%O2 for 24 hr. Consistent
with observations in HCT116 cells, overexpressed HIF-1a
restored the hypoxia-induced increase in G1 phase and
decrease in S phase populations (p < 0.05) in WT8 cells,
while HIF-2a overexpression continued to elevate the pro-
portion of cells in S phase (Figure 2B; p < 0.01). Prolifera-
tion was also assessed in these cells and found to corre-
late with hypoxia-induced changes in cell-cycle profile
(Figure 2C). By coexpressing HIF-1a and HIF-2a, we con-
firmed that HIF-1a induces cell-cycle arrest in WT8 cells,
eliminating the possibility that they exhibit a tissue-
specific cell-cycle response to hypoxia. To further support
these data, we used the pVHL-rescued RCC4 T3-14 cell
line, which expresses both HIF-1a and HIF-2a (Hu et al.,
2003) stably transduced with shRNAs targeting either
HIF-1a or HIF-2a or an empty vector (Lum et al., 2007).
HIF-a subunit expression was assessed by immunoblot,
showing essentially complete knockdown of HIF-1a
and >75% knockdown of HIF-2a (Figure 2D). The efficacy
of knockdown was confirmed by measuring expression of
HIF-a shared and unique targets VEGF, PGK, and Oct4
(Figure S2A). Next, BrdU incorporation was measured
after 0, 24, or 48 hr hypoxia. While clones transduced
with the empty vector showed a gradual decrease in
percentage of cells in S phase, those with HIF-2a knock-
down showed a more precipitous decrease. In direct con-
trast, pVHL-rescued RCC4 cells with HIF-1a knockdown
showed increased percentage of cells in S phase (Fig-
ure S2B). When cell counts were performed, only a small
proliferation decrease was noted under hypoxia in vec-
tor-transfected cells (Figure S2C), whereas a substantial
increase was noted with HIF-1a knockdown and aCancer Cell 11, 335–347, April 2007 ª2007 Elsevier Inc. 337
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HIF-2a Enhances c-Myc ActivityFigure 2. HIF-1a and HIF-2aHave Antag-
onistic Effects onCell-Cycle Progression
(A) HIF-a subunit expression in WT8 cells sta-
bly overexpressing HIF-1a (1.1, 1.2, 1.3) or
HIF-2a (2.1) after 24 hr at 0.5% O2.
(B) Summary of changes in BrdU incorporation
in WT8 cells overexpressing HIF-1a or HIF-2a
after 24 hr hypoxia. Results averaged from
at least three experiments; error bars indi-
cate ±1 SEM, *p < 0.05, **p < 0.01.
(C) Proliferation measured by serial cell counts
under normoxia (N) or hypoxia (H); data from
one representative experiment. Error ±1 SD.
(D) HIF-a subunit expression in pVHL-rescued
RCC4 cells transduced with empty vector
(p1, p2) or shRNA against HIF-1a (142, 144)
or HIF-2a (241, 242) after 24 hr at 0.5% O2.
(E) Proliferation in clones with HIF-1a or HIF-2a
knockdown, measured by serial cell counts
under normoxia (N) or hypoxia (H); data from
one representative experiment. Error bars
indicate ±1 SD.substantial decrease was noted with HIF-2a knockdown.
All clones showed indistinguishable proliferation under
normoxic conditions (Figure 2E). Thus, HIF-2a enhances
cell-cycle progression in a fashion that is antagonized in
a dose-dependent manner by HIF-1a, suggesting that
both HIF-a subunits act on the same pathway. These ef-
fects on proliferation in RCC4 are particularly notable, as
selective knockdown of each HIF-a disrupts a balanced
effect on hypoxic proliferation to either potently enhance
it (in the presence of HIF-2a alone) or repress it (with
only HIF-1a). This analysis is particularly relevant to RCC
development, since most human renal tumors exhibit
HIF-1a loss while maintaining HIF-2a during tumor pro-
gression (Mandriota et al., 2002; Raval et al., 2005).
HIF-2a Enhances the Expression of c-Myc Target
Genes in a c-Myc-Dependent Fashion
To investigate the role of c-Myc in these cell-cycle
changes, we assessed hypoxic expression of c-Myc tar-
gets p21 and p27 (repressed by c-Myc), as well as Cyclin
D2 and E2F1 (activated by c-Myc). Although additional
factors also regulate these genes, we will refer to them
as ‘‘c-Myc targets’’ to differentiate them from direct HIF
targets such as PGK and Oct4. Under the conditions de-
scribed above, we observed increased p21 and p27338 Cancer Cell 11, 335–347, April 2007 ª2007 Elsevier Inc.mRNA expression in hypoxic HCT116 cells, consistent
with attenuated repression by c-Myc. Conversely, hypoxic
WT8 cells exhibited decreased p21 and p27 mRNA ex-
pression, consistent with enhanced repression by c-Myc
(Figure 3A). We observed the opposite effect on c-Myc-
activated targets: Cyclin D2 and E2F1 mRNA levels were
decreased in hypoxic HCT116 cells and increased in hyp-
oxic WT8 cells (Figure 3B). These results were confirmed
by immunoblot assays on extracts from cells grown at
21% O2 or 0.5% O2 for 48 hr (Figure 3C). While the data
demonstrate relatively subtle changes in expression,
they are consistent with those commonly observed for
c-Myc (Bouchard et al., 1999; Coller et al., 2000). To con-
firm the antagonism betweenHIF-1a andHIF-2a on c-Myc
target genes, p27 and Cyclin D2 expression was also
assessed in stable WT8 lines overexpressing HIF-1a and
HIF-2a. Consistent with the cell-cycle analysis, increased
HIF-1a expression correlated with dose-dependent
increases in p27 induction and Cyclin D2 repression, while
increased HIF-2a expression correlated with decreased
p27 expression and increased Cyclin D2 expression, as
observed in the parental cell line (Figure 3D).
To further extend these observations, two other model
systems were analyzed. First, we measured mRNA and
protein changes in p27 and Cyclin D2 in the RCC4 cell
Cancer Cell
HIF-2a Enhances c-Myc ActivityFigure 3. Tumor Cell Lines Expressing
HIF-1a or HIF-2a Exhibit Differential Hyp-
oxic Effects on Cell-Cycle Regulators
(A) Expression of c-Myc repressed targets p21
and p27 in HCT116 and WT8 following 24, 48,
or 72 hr at 0.5%O2. Resultsmeasured byQRT-
PCR and averaged from four experiments;
error bars indicate ±1 SEM. As described in
the text, HIF-1a-expressing HCT116 cells and
HIF-2a-expressing WT8 cells exhibit opposite
responses to hypoxia with respect to c-Myc
target expression.
(B) Expression of c-Myc activated targets
Cyclin D2 and E2F1 in HCT116 and WT8 as
above.
(C) Western blot analysis of c-Myc target ex-
pression in HCT116 and WT8 following 48 hr
hypoxia.
(D) Expression of c-Myc targets in WT8 cells
overexpressing HIF-1a or HIF-2a following
24 hr at 0.5% O2.
(E) Change in p21 and p27 interaction with
CDK2 assessed by CDK2 IP following 48 hr
hypoxia in HCT116 and WT8.lines described above. In empty-vector-transduced cells,
little change was detected in mRNA or protein levels of
these targets. In clones with HIF-1a knockdown, de-
creased p27 and increased Cyclin D2 were observed,
while in clones with HIF-2a knockdown, increased p27
and decreased Cyclin D2 were observed (Figure S2E).
These findings correlate with the cell-cycle changes
described above, though a minor decrease in S phase
percentage is noted in the vector-transduced cells with
no change in c-Myc targets. This is likely to be a result
of HIF-independent effects of the stringent level of hyp-
oxia (0.5%O2) used in this study. Second, to use a defined
genetic system that is relatively undifferentiated and un-
likely to have the mutational load of a human tumor cell
line, we produced embryonic ECs (Mansfield et al.,
2005) from day 8.5 embryos harboring targeted deletions
of Hif-1a (Carmeliet et al., 1998) or Hif-2a (Compernolle
et al., 2002). Six lines were analyzed in total, with two
Hif-1a and two Hif-2a null lines, and a WT littermate con-
trol for each. Results from one representative cell line from
each genotype are shown. First, HIF-a expression and tar-
get-gene induction were confirmed (Figures S3A and
S3B). Next, we measured mRNA expression of c-Myc tar-
gets p27 and Cyclin D2. No change in p27 was detected
in hypoxic WT lines, whereas p27 mRNA levels increased
in hypoxic cells expressing only HIF-1a and decreased in
cells expressing only HIF-2a (Figure S3C, upper panel).
For Cyclin D2, we observed that all HIF-2a-expressingcell lines (i.e., WT or Hif-1a/) exhibited increased
mRNA expression under hypoxia, while only the Hif-
2a/ cells exhibited decreased Cyclin D2 mRNA levels
(Figure S3C, lower panel). Western blot analysis con-
firmed the observed mRNA changes (Figure S3D). Thus,
consistent HIF-a-mediated modulation of c-Myc-influ-
enced cell-cycle regulators was observed in multiple cell
systems.
As the biological effects of c-Myc are mediated through
coordinated regulation of multiple factors influencing the
G1-S phase transition, cyclin-dependent kinase 2 (CDK2)
immunoprecipitations (IPs) were performed on hypoxic
HCT116 and WT8 cells at 48 hr and tested for coprecipi-
tated p21 and p27. We observed substantially increased
levels of p21 associated with CDK2 in hypoxic HCT116
cells, while less change was observed for p27. However,
it should be noted that HCT116 cells express higher levels
of p21 than p27. In direct contrast, p27 association with
CDK2 was almost completely abrogated in hypoxic WT8
cells, while minimal p21 was detected (Figure 3E and
data not shown). Therefore, changes in c-Myc target ex-
pression correlate with more dramatic differences in
CDK2 complex components, consistent with the hypoxic
effects on cell-cycle progression observed above.
The data suggested a correlation between HIF-a effects
on cell-cycle progression and c-Myc target gene expres-
sion. To confirm that gene expression and cell-cycle
changes were a direct result of hypoxic activation of theCancer Cell 11, 335–347, April 2007 ª2007 Elsevier Inc. 339
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HIF-2a Enhances c-Myc ActivityHIF-a subunits and test a requirement for c-Myc, HCT116
and WT8 cells were transfected with siRNA against
HIF-1a, HIF-2a, and c-Myc, or a control siRNA. Each
siRNA achieved greater than 60% knockdown of its target
(Figure 4A). c-Myc knockdown sometimes correlated with
less HIF-1a or HIF-2a expression. We believe this to be
a direct result of c-Myc knockdown, as it occurred in
a dose-dependent fashion, and with two separate siRNAs
against c-Myc (data not shown). HIF effects on p27 were
not altered by the control siRNA at 20 hr hypoxia
(Figure 4B). When treated with siRNA against HIF-1a, hyp-
oxic HCT116 cells failed to induce p27 mRNA, and when
treatedwith siRNA against HIF-2a, theWT8 cells no longer
exhibited decreased p27 expression. Finally, c-Myc
siRNA resulted in high p27 mRNA levels, with no effect
of hypoxia on either cell type. Similarly, Cyclin D2 levels
were not decreased in hypoxic HCT116 cells treated
with HIF-1a siRNA or increased in hypoxic WT8 cells
treated with HIF-2a siRNA. With c-Myc siRNA, low Cyclin
D2 levels were observed in all conditions (Figure 4C). Fur-
thermore, when cells were tested by BrdU incorporation
after 48 hr hypoxia, knockdown of the HIF-1a in HCT116
and HIF-2a in WT8 abrogated the effect of hypoxia on
cell-cycle progression (Figure 4D). These data indicate
that HIF-1a and HIF-2a are required to alter hypoxic
cell-cycle progression and modulate c-Myc target gene
expression in a c-Myc-dependent manner.
HIF-a Subunits Regulate c-Myc Promoter Binding
and Interactions with Sp1, Miz1, and Max
To elucidate the mechanism(s) by which HIF-a subunits
regulate c-Myc activity, we tested the effects of hypoxia
on c-Myc promoter occupancy by chromatin IP (ChIP) in
HCT116 and WT8 cells. ChIP was performed for c-Myc,
HIF-1a, HIF-2a, and p53 and analyzed with QRT-PCR.
The data are represented as the average fold difference
between IP with a specific antibody and the background
signal of an isotype-matched control. Results are aver-
aged from four separate experiments with hypoxic treat-
ment, ChIP, and PCR analysis performed independently.
For these experiments, three c-Myc-repressed targets
(p21, p27, and p15) were analyzed with primers at the
Inr, and three c-Myc-activated targets (ODC, Cyclin D2,
and E2F1) were analyzed, with primers directed at their
E box elements, centered at bases 1158, 282 (in intron
1), and 354, respectively. In all cases, the signal de-
tected for c-Myc ChIP of normoxic HCT116 cells de-
creased to near-background levels under hypoxia. When
c-Myc ChIP was performed in WT8 cells, a substantial in-
crease in the signal from all promoters tested was ob-
served in hypoxic cells (Figure 5A). Previous studies
have demonstrated HIF-1a binding to the Inr of p21 and
MutSa (Koshiji et al., 2004, 2005). We also detected
HIF-1a binding to the p21 Inr and the VEGF HRE (centered
at base 968) in HCT116 cells and HIF-2a binding to the
same sites in WT8 cells. However, neither HIF-a subunit
bound to any of the other c-Myc DNA-binding regions
tested (Figures S4A and S4B). These data showed that
HIF-2a effects on c-Myc-regulated genes correlated340 Cancer Cell 11, 335–347, April 2007 ª2007 Elsevier Inc.with increased levels of c-Myc binding to their promoters,
but that HIF-2a DNA binding near c-Myc was not required
for hypoxic regulation of c-Myc targets. To confirm the ef-
fect of each HIF-a subunit on c-Myc promoter binding in
an isogenic cell system, we repeated this analysis in
HEK293 cells which expressed Myc-tagged normoxically
stable double proline mutants (DPM) of the HIF-a subunits
with doxycycline induction (Figure S5A; Hu et al., 2003). As
before, HIF-1a led to decreased c-Myc DNA binding and
Figure 4. HIF-a Effects on p27 and CyclinD2 Levels Require
c-Myc
(A) Western blot analysis showing siRNA inhibition of HIF-1a (H1),
HIF-2a (H2), and c-Myc (M) expression, as well as a luciferase control
(C) in HCT116 and WT8 cells.
(B) QRT-PCR analysis showing expression of p27 in siRNA-treated
cells after 20 hr at 0.5% O2. Results measured by QRT-PCR from
four experiments are shown; error bars indicate ±1 SEM.
(C) QRT-PCR analysis showing expression of Cyclin D2 in siRNA
treated cells. Results measured as above.
(D) Cell-cycle progression measured by BrdU incorporation in asyn-
chronous HCT116 cells treated with control or HIF-1a siRNA and
WT8 cells treated with control or HIF-2a siRNA at 21% O2 (N) or
0.5% O2 (H) for 48 hr. Results averaged from three experiments are
shown; error bars indicate ±1 SEM, *p < 0.05.
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HIF-2a Enhances c-Myc ActivityFigure 5. ChIP Demonstrates Altered
c-Myc Promoter Occupancy in Hypoxic
Cells
(A) HCT116 and WT8 cells were grown at 21%
O2 (N) or 0.5% O2 (H) for 20 hr and then as-
sayed by ChIP. Following IP with antibody
against c-Myc or isotype control, extracts
were assessed by QRT-PCR using SYBR
green. The graphs show the fold difference
between c-Myc IP and Rabbit IgG control
(background) with results from four separate
experiments; error bars indicate ±1 SEM.
(B) Time course of HIF-a protein induction in
HCT116 and WT8 at 1, 2, and 20 hr at 0.5%
O2. Asterisk indicates a nonspecific band.
(C) QRT-PCR time course of HIF target gene
induction at the same time points as above.
Results averaged from three experiments;
error bars indicate ±1 SEM.
(D) c-Myc promoter binding in HCT116 and
WT8 cells incubated at 0.5% O2 for 1 or 2 hr,
then analyzed by ChIP as above. Results
from four independent experiments are shown;
error bars indicate ±1 SEM.HIF-2a led to increased c-Myc DNA binding (Figure S5B).
Similarly, Myctag IPs (for the HIF-a subunits) showed
HIF-a DNA binding to p21 Inr and the VEGF HRE, but no
other assayed sites (Figure S5C). A control PCR reaction
was performed with primers targeting a p53-binding site
at 2.3 kB on the p21 promoter. Confirming antibody
specificity, the signal was detected with p53 ChIP but no
other antibody tested (Figure S4C and S5D; Koshiji
et al., 2004).
The data strongly suggest a model in which HIF-a sub-
units alter c-Myc promoter binding, as opposed to its abil-
ity to activate transcription. To understand the underlying
mechanism(s) for these effects, we determined whether
HIF transcriptional activity is required. ChIP was per-
formed as above, but cells were incubated at 0.5% O2
for only 1–2 hr. At these time points, HIF-a protein induc-
tion is observed (Figure 5B), but induction of HIF-a target
genes is not (Figure 5C). HCT116 cells exhibited a de-
crease in c-Myc binding to p21, p27, and Cyclin D2 pro-
moters at 0.5%O2, while enhanced binding was observed
in WT8 cells (Figure 5D). As an additional control, ChIP
was performed on cells pretreated with Actinomycin D,
and similar results were observed (data not shown).
Thus, we concluded that the effects of HIF-1a and
HIF-2a on c-Myc promoter binding were independent of
their respective transcriptional targets.As c-Myc activity is a function of its protein level, we
investigated hypoxic effects on c-Myc accumulation, as
well as that of its binding partners Sp1, Miz1, and Max,
and its competitor Mad1. No consistent changes in pro-
tein levels were detected in HCT116 and WT8 cells grown
for 4 or 20 hr at 0.5% O2 (Figure S6A). Assessment of
c-Myc mRNA levels and protein stability revealed no con-
sistent changes under hypoxia (data not shown). Of note,
hypoxic culture for 4 or 20 hr correlated with a substantial
decrease in c-Myc coprecipitation with Sp1, Miz1, and
Max in HCT116 cells and an increase in c-Myc coprecipi-
tation with these proteins in WT8 cells, albeit less dramat-
ically than the decrease seen in HCT116 cells (Figure 6A).
When Mad1 IP was performed, the opposite result was
observed: increased Mad1/Max association in hypoxic
HCT116 cells and decreased association in hypoxic
WT8 cells. To confirm these data, IP was also performed
for Sp1, Miz1, and Max. As before, we observed de-
creased coprecipitation of these proteins with c-Myc in
hypoxic HCT116 cells and increased coprecipitation in
hypoxic WT8 cells (Figure 6B).
To identify a transcription-independent mechanism by
which HIF-1a and HIF-2a might alter c-Myc/Max binding,
we investigated the interaction of HIF-1a and HIF-2a with
Sp1, Miz1, and Max. In HCT116 cells, HIF-1a coprecipi-
tated with Sp1 and Max, whereas in WT8 cells HIF-2aCancer Cell 11, 335–347, April 2007 ª2007 Elsevier Inc. 341
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Correlate with Differential c-Myc Inter-
actions with Sp1, Miz1, and Max
(A) Coprecipitation of Sp1, Miz1, and Max after
c-Myc IP and Max after Mad1 IP in HCT116
and WT8 cells grown at 0.5% O2 for 4 and
20 hr.
(B) Coprecipitation of c-Myc after Sp1, Miz1, or
Max IP in HCT116 and WT8 cells grown under
hypoxia for 20 hr.
(C) HIF-1a and HIF-2a coprecipitation after
Sp1, Miz1, and Max, or isotype control IP in
HCT116 and WT8 cells treated with DFX for
4 hr.
(D) Vector control (V1) and HIF-1a-over-
expressing cell lines were cultured at 0.5%
O2 for 20 hr, and Max IP was performed and
analyzed for coprecipitated HIF-1a, HIF-2a,
and c-Myc.
(E) Vector control (V1) and HIF-2a-over-
expressing cell lines were cultured at 0.5%
O2 for 20 hr, and Max IP was performed and
analyzed for coprecipitated HIF-2a and c-Myc.coprecipitated only with Max. Interestingly, we noted
a difference in the stoichiometry of these interactions:
the HIF-1a/Max complex accounted for approximately
0.25% of cellular HIF-1a, whereas the HIF-2a/Max com-
plex accounted for 2% of cellular HIF-2a (Figure 6C). Con-
trol immunoblots were performed for specificity of the
Max IP, showing no coprecipitation with the abundant
transcription factor Rb (data not shown). Next, using
WT8 cell lines overexpressing HIF-1a (1.1, 1.2, and 1.3)
and HIF-2a (2.1, 2.2, and 2.3), we tested for effects of
HIF-a levels on c-Myc/Max binding. When the HIF-1a
overexpressing cell lines and a vector control (V1) were
incubated at 0.5% O2 for 20 hr, increasing levels of
HIF-1a/Max binding correlated with decreasing c-Myc/
Max binding and HIF-2a/Max binding, despite similar
levels of c-Myc and Max in whole-cell lysates. As noted
before, there is a decrease in HIF-2a expression with in-
creasing levels of HIF-1a (Raval et al., 2005). However,
the decrease in HIF-2a/Max binding is greater than the dif-
ference in expression (Figure 6D). On the other hand,
when HIF-2a overexpressing cell lines were incubated un-
der hypoxia, a dose-dependent increase in c-Myc/Max
binding was observed, correlating with the increase in
HIF-2a/Max binding (Figure 6E). There was no difference342 Cancer Cell 11, 335–347, April 2007 ª2007 Elsevier Inc.in c-Myc/Max binding in any of these lines under normoxia
(Figures S6B and S6C). These data demonstrate the for-
mation of complexes containing HIF-1a and Max or
HIF-2a and Max. Both HIF-1a inhibition of c-Myc/Max
complex formation and HIF-2a promotion of c-Myc/Max
complex formation correlated with the expression level
of each a subunit and its interaction with Max, suggesting
a direct effect on c-Myc complex composition.
HIF-2a Promotes Cell-Cycle Progression
in NIH3T3 Cells
Having observed a differential effect of HIF-1a and HIF-2a
on c-Myc targets in multiple cell types, we next confirmed
their impact on cell-cycle progression in NIH3T3 cells,
which exhibit well-characterized cell-cycle responses.
For this purpose, we isolated NIH3T3 cell clones with
doxycycline-responsive expression of DPM-HIF-1a-Myc-
tag and DPM-HIF-2a-Myctag, allowing the separation of
the HIF-a subunits from any HIF-independent hypoxic ef-
fects on cell-cycle progression. Two clones expressing
HIF-1a (151 and 101) and two expressing HIF-2a (265
and 201) were used for further analysis. The inducible
HIF-1a was expressed at a level similar to that induced
by 0.5% O2. While there is no endogenous HIF-2a in
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Cells Expressing Normoxically Stable
HIF-1a orHIF-2aShowDifferential Effects
on Cell-Cycle Progression
(A)Western blots showingHIF-a subunit expres-
sion following 24or 48 hr treatmentwith doxycy-
cline.
(B) Representative FACS plot at 0 and 2 days
doxycycline from a HIF-1a (151)- and HIF-2a
(201)-expressing clone.
(C) Cell-cycle progression in doxycycline-regu-
lated 3T3s (clones 151 and 201) measured by
BrdU incorporation. Results from three experi-
ments are shown; error bars indicate ±1 SEM,
*p < 0.05.
(D) Proliferation measured by serial cell counts;
data from one representative experiment.
Error ±1 SD.NIH3T3 cells, doxycycline induction of HIF-2a produced
similar increases in VEGF mRNA to either hypoxia or
HIF-1a induction (data not shown). Figure 7A shows the
stable induction of each transgene after 48 hr doxycycline
treatment, with some baseline HIF-2a expression in clone
265. The effect of doxycycline treatment on cell-cycle pro-
gression was assayed by BrdU incorporation. Represen-
tative FACS plots are shown (Figure 7B). Results from
four independent experiments were averaged, and a sta-
tistically significant decrease in the percentage of HIF-1a-
induced cells in S phase and increase in the percentage in
G1 phase (p < 0.05) after 24 or 48 hr of doxycycline treat-
ment was observed (Figure 7C, upper panel). Interestingly,
a statistically significant increase in percentage in S phase
(p < 0.05) was noted after 24 but not 48 hr in the HIF-2a-
inducible lines (Figure 7C, lower panel). When proliferation
rates were measured, a significant decrease was ob-
served in HIF-1a-inducible cells following doxycycline
treatment, and a significant increase was observed in
HIF-2a-inducible cells, consistent with their cell-cycle pro-
files (Figure 7D). Although HIF-2a enhanced S phase entry
for 1 day only, this was sufficient to cause increased cell
numbers for the course of the experiment. We concluded
that HIF-a subunit effects on cell-cycle progression in
tumor cell lines can be generalized to multiple cell types,
including those with intact cell-cycle regulation, and do
not require HIF-independent hypoxic effects.HIF-2a Enhances RasV12G/c-Myc Transformation
of Primary MEFs
Given that HIF-2a promotes RCC tumor development
(Mandriota et al., 2002), we tested HIF-2a’s ability to pro-
mote transformation of primary MEFs. For this purpose,
passage 4 MEFs from day 13.5 embryos were transfected
with DPM-HIF-1a-FLAG or DPM-HIF-2a-FLAG, as well as
RasV12G, c-Myc, or both. Cells were allowed to grow to
confluency and assessed for focus formation by Wright-
Giemsa staining 30 days later. As demonstrated in a repre-
sentative assay (Figure 8A), cotransfection of HIF-2a with
RasV12G and c-Myc resulted in a 32% increase in focus
formation compared to RasV12G and c-Myc alone,
whereas cotransfection of HIF-1a resulted in a 25% de-
crease. The complete analysis of three experiments
(Figure 8B) reveals a statistically significant difference be-
tween RasV12G/Myc with an empty vector, DPM-HIF-1a-
FLAG and DPM-HIF-2a-FLAG (p < 0.01 in all cases). Inter-
estingly, DPM-HIF-2a-FLAG cotransfection with c-Myc
alone resulted in a 41% increase (p < 0.05), while DPM-
HIF-1a-FLAG resulted in a 32% decrease (p < 0.05).
Foci were picked from these plates and cell lines gener-
ated, all of which formed colonies in soft agar (Figure 8C).
These clones were also evaluated for expression of the
transfected proteins. Overexpressed c-Myc and RasV12G
were detected in all established cell lines relative to
mock-transfected controls, with c-Myc overexpressionCancer Cell 11, 335–347, April 2007 ª2007 Elsevier Inc. 343
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mation by Primary MEFs
(A) Representative Wright-Giemsa-stained
plates from MEFs transfected with empty
pcDNA3.1 and pBABE vectors, RasV12G,
c-Myc, DPM-HIF-1a, and DPM-HIF-2a. Scale
bar is 1 cm.
(B) Colony counts from all transfection combi-
nations are shown. Results from three experi-
ments; error bars indicate ±1 SEM, *p < 0.05,
**p < 0.01.
(C) Colony formation in soft agar by cell lines
derived from foci. Scale bar, 200 mM.
(D) Immunoblot analysis of HIF-2a, c-Myc, and
Ras overexpression in representative clones
obtained from foci picked from plates trans-
fected with c-Myc, RasV12G, pCDNA3.1,
DPM-HIF-1a, and DPM-HIF-2a. Asterisk indi-
cates endogenous protein.
(E) Model for HIF-a regulation of c-Myc activity.
We propose that HIF-1a specifically disrupts
c-Myc/Max and c-Myc/Sp1 complexes, allow-
ing more Mad/Max interaction and DNA bind-
ing. On the other hand, we hypothesize that
HIF-2a stabilizes c-Myc/Max complexes, in
turn promoting c-Myc DNA binding at both E
boxes and Inrs.leading to repression of endogenous c-Myc (endogenous
protein is indicated with an asterisk). Interestingly, it ap-
pears that cell lines obtained from plates transfected
with DPM-HIF-1a-FLAG failed to maintain expression of
this transgene, but those transfected with DPM-HIF-2a-
FLAG did (Figure 8D and data not shown). In aggregate,
these data support a role for HIF-2a in promoting transfor-
mation and suggest that HIF-1a can inhibit it.
DISCUSSION
In this study, we found that HIF-2a promotes c-Myc tran-
scriptional activity and cell-cycle progression in renal car-
cinoma cells, NIH3T3 cells, HEK293 cells, and embryonic
ECs. Furthermore, HIF-2a promotes MEF transformation
in concert with RasV12G and c-Myc. We believe that
this pathway contributes substantially to the proliferation
of normal and transformed cells under hypoxia, as well
as the transformation of cells that have lost the VHL tumor
suppressor. The effect of HIF-2a on c-Myc is of particular
interest, as it directly opposes that of HIF-1a, allowing344 Cancer Cell 11, 335–347, April 2007 ª2007 Elsevier Inc.differential control of cell-cycle progression based on
HIF-a subunit expression.
Previous data have demonstrated that HIF-1a modu-
lates c-Myc function in hypoxic cells. In those studies,
HIF-1a was shown to inhibit c-Myc transcriptional activity
by inhibiting DNA binding, specifically through competi-
tion for Sp1 (Koshiji et al., 2004, 2005; To et al., 2006).
We have repeated these findings and also observed
HIF-1a/Max binding, which may block c-Myc/Max inter-
action. While in previous studies HIF-1a also bound DNA
in the same location as c-Myc, we observed HIF-a binding
at the p21 Inr but not the five other c-Myc target promoters
tested, suggesting that displacement is not required to
modulate c-Myc. HIF-2a also appears to regulate c-Myc
by modulating c-Myc/Sp1, c-Myc/Miz1, and c-Myc/Max
interactions. When HIF-2a is present, more c-Myc/Max,
c-Myc/Miz, and c-Myc/Sp1 complexes and fewer Mad/
Max complexes are detected compared to normoxia.
HIF-2a coprecipitated with Max, suggesting that it also in-
teracts with these proteins, either through direct binding
or as part of a larger complex. Based on these data and
those previously reported (Koshiji et al., 2005; To et al.,
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lieve that the presence of HIF-1a directly blocks c-Myc in-
teraction with its DNA-binding partners. HIF-2a, on the
other hand, might promote c-Myc interaction with Max,
and thus Sp1 and Miz1, by recruiting it directly to these
complexes, or by stabilizing these complexes once they
are formed. This might occur by selectively blocking
Max interaction with Mad1, which competes with c-Myc
for available cellular Max. Understanding the precise ef-
fects of HIF-1a/Max, HIF-1a/Sp1, and HIF-2a/Max inter-
actions will require further analysis of the multimeric com-
plexes formed.
Multiple HIF-2a targets besides c-Myc promote prolifer-
ation and transformation and are necessary for tumor
growth. HIF-2a directly activates the expression of Oct4,
Cyclin D1, and TGFa, each of which can promote transfor-
mation in MEFs or NIH3T3 cells (Alt et al., 2000; Gidekel
et al., 2003; Twardzik et al., 1982). HIF-2a activation of
these targets is not responsible for transformation in our
study, as Oct4 and TGF-a were not detected in trans-
formed MEF cell lines or NIH3T3 cells described above,
and similar mRNA and protein levels were observed for
Cyclin D1 regardless of HIF-a expression (data not
shown). However, the activation of other HIF-2a targets
may collaborate in c-Myc-driven proliferation and trans-
formation by blocking its effects on apoptosis.
Although HIF-2a is unique in its ability to promote prolif-
eration and transformation, it shares HIF-1a’s effects on
angiogenesis, invasion, and metabolism, all of which con-
tribute to tumor growth and progression. Many clinical
studies have correlated the presence of either HIF-a sub-
unit with poor patient outcomes. However, differential ef-
fects of the HIF-a subunits may play a key role in cells that
have more intact cell-cycle control, as is the case for pre-
neoplastic cells as well as many scientific model systems.
Similarly, the amplitude of HIF-a activation may alter
which pathways or effects are more dominant. For exam-
ple, HIF-1a activation in Vhl/ Ras-transformed MEFs in-
hibits subcutaneous allograft growth (Mack et al., 2005),
while Hif-1a/ Ras-transformed MEFs form smaller sub-
cutaneous tumors than their WT counterparts (Ryan et al.,
2000). Notably, the Vhl/MEFs exhibited enhanced vas-
cularity but limited proliferation in vitro, whereas the
Hif-1a/ MEFs exhibited limited VEGF expression. It
appears that hypoxic HIF-1a activation is necessary for tu-
mor angiogenesis, whereas continuous activation inhibits
cell-cycle progression. Modulation of hypoxic cell survival
can also change tumor behavior, as observed in a recent
study where HIF-1a or HIF-2a were overexpressed in gli-
oma cells (Acker et al., 2005). Glioma is well known for ex-
tensive hypoxic domains with substantial cell death. This
was promoted by HIF-a overexpression, leading to de-
creased tumor size due to apoptosis (Acker et al., 2005).
Thus, each HIF-a may have the potential to be a tumor
promoter or suppressor depending on the biology of
a given tumor type and its stage of development.
These data have significant implications for tumor initi-
ation and progression in multiple tumor types. In the con-
text of RCC, several HIF-2a targets appear to be importantin tumor initiation and progression, including VEGF, Oct4,
and TGFa. Our data showing that HIF-2a promotes MEF
transformation, whereas HIF-1a inhibits it, support the ev-
idence that relative increases in HIF-2a activity, as well as
HIF-1a loss, correlate with the acquisition of dysplastic
characteristics in VHL/ renal lesions (Mandriota et al.,
2002; Raval et al., 2005). As VEGF, Oct4, and Cyclin D1
are not relevant to MEF transformation in our studies,
these data also suggest a unique role for HIF-2a-mediated
c-Myc activation in RCC initiation. Our findings are also
relevant to other common malignancies. In recent studies
of neuroblastoma and colorectal and non-small-cell lung
cancer, which express both a subunits, the expression
of HIF-2a was more conclusively associated with a poor
prognosis than HIF-1a (Giatromanolaki et al., 2001; Holm-
quist-Mengelbier et al., 2006; Yoshimura et al., 2004).
Given the data connecting c-Myc (or its family member
n-Myc) to each tumor type, it is likely that HIF-2a-medi-
ated enhancement of c-Myc activity has a role in these,
and other, human cancers.
EXPERIMENTAL PROCEDURES
Cell Culture
HCT116 (obtained from ATCC) andWT8 cells (kind gift fromW.G. Kae-
lin) were cultured in DMEM with 10% FBS (Gemini Biosystems), 2 mM
glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin, and 0.1mM
MEM nonessential amino acids. MEFs were maintained in DMEMwith
10% FBS (Hyclone) and the supplements above. ECs were derived
and cultured as described (Mansfield et al., 2005). NIH3T3 cells
(ATCC) were stably transfected with the reverse Tet-Activator accord-
ing to themanufacturer’s specifications (Clontech, Mountainview, CA),
and then with pTRE-DPM-HIF-1a-Myctag and pTRE-DPM-HIF-2a-
Myctag. Once clones were isolated, these lines (and the Tet-on
HEK293 cells) were maintained in DMEM, 10% FBS (Clontech Tet-
approved), 150 mg/ml Hygromycin B, and the supplements listed
above. Doxycycline (Clontech) was used at 0.5 mg/ml in NIH3T3 cells
and 2 mg/ml in HEK293 cells.
Hypoxia
Hypoxia (0.5%O2, 5%CO2, 94.5%N2) was achieved using an In Vivo2
hypoxic workstation (Ruskinn Technologies) or in a positive pressure
chamber receiving gas from a custom-mixed tank (Airgas). DFX
(Calbiochem) was used as a hypoxia mimetic at a final concentration
of 200 mM.
Cell-Cycle Analysis
For these experiments, cells were plated at a density such that they
would be 50% confluent on the day of analysis. Treatment (hypoxia
or doxycycline) was then initiated over the next several days, so that
all cells were in culture for the same amount of time and at similar con-
fluency when harvested. BrdU analysis was performed following the
standard protocol (Becton Dickinson) after a 20 min pulse with
10 mM BrdU. Cells were stained with Alexa 488 anti-BrdU (Invitrogen)
and 0.1 M propidium iodide and analyzed in an LSR FACS machine
(Becton Dickinson). For proliferation analysis, 104 cells were plated
on 6 cm2 plates, and two plates were counted per time point in a hemo-
cytometer over 8 days. Transformation assays are described in the
Supplemental Experimental Procedures.
QRT-PCR
Total RNA was extracted from cells with Trizol reagent following the
manufacturer’s instructions (Invitrogen). cDNA was produced from
2 mg of RNA using Superscript II (Invitrogen) with random hexamerCancer Cell 11, 335–347, April 2007 ª2007 Elsevier Inc. 345
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HIF-2a Enhances c-Myc Activityprimers (Boehringer Mannheim). Primers against 18S (Applied Biosys-
tems) were used for the endogenous control in DD CT analysis. Primer
sets were generated against human and mouse VEGF, PGK, Oct4,
p27, and Cyclin D2, as well as human p21 and E2F1 (sequences avail-
able on request). Analysis was performed in an Applied Biosystems
7900HT Sequence Detection System, with amplification quantified
with SYBR green.
siRNA Analysis
Specific knockdown was achieved using siRNAs against HIF-1a
(Hs_HIF1_2 and 3), HIF-2a (Hs_HIF1_2 and 4) and c-Myc (Hs_Myc_2
and 3) or a control siRNA (all from Qiagen). Transfection was per-
formed using HiPerfect reagent (Qiagen) as directed. Six hours after
transfection, media were changed and cells were placed under hyp-
oxia for 20 hr (for expression analysis) or 48 hr (for cell-cycle analysis).
Cells were harvested for protein and RNA analysis as described above.
IP and Western Blot Analysis
For IP assays, cells were lysed in 25 mM Tris (pH 8.0), 100 mM NaCl,
and 1% Triton X-100 containing Complete protease inhibitors (Roche)
and 200 mM DFX. For all other Western blots, lysis was performed in
RIPA. Subcellular fractionationwas performed as previously described
(Qu et al., 2004). Antibodies and protocol for ChIP are listed in the Sup-
plemental Data.
Supplemental Data
The Supplemental Data include six supplemental figures and Supple-
mental Experimental Procedures and can be found with this article on-
line at http://www.cancercell.org/cgi/content/full/11/4/335/DC1/.
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